Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071296 | 1.00 | CCNC (0.52) | CCNCCDK8KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL2846706 | 0.85 | CYP11B2 (0.42) | CCNCCDK8KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL2846708 | 0.85 | CYP11B2 (0.42) | CCNCCDK8KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL22366337 | 0.83 | CDK8 (0.56) | CCNCCDK8KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL21001955 | 0.82 | SMN1; SMN2 (0.39) | CCNCCDK8KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL29484670 | 0.81 | KMT2A (0.49) | CCNCCDK8KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL5292811 | 0.81 | HDAC8 (0.64) | KMT2AKDM4ESMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL3628443 | 0.81 | KMT2A (0.49) | CCNCCDK8KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL3628444 | 0.81 | KMT2A (0.49) | CCNCCDK8KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL23606857 | 0.76 | KMT2A (0.49) | CCNCCDK8KMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014752-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-01-19 | — | — | US | disclosed |
| WO-2005019177-A1 | AMINOPIPERIDINE AMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019177-A1 | AMINOPIPERIDINE AMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20030114441-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114441-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | CA3, GAP43, SLC1A2 | CCNC 609/4885CDK8 1483/4885KMT2A 1196/4885 |
| US-20060014752-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | GAP43, GABRE, CA3 | CCNC 1013/4885CDK8 1922/4885KMT2A 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.